Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.

Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...

Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), ...

Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally.

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) saw unusually-high trading volume on Friday after Bank of America raised their price target on the stock from $18.00 to $21.00. Bank of ...

Morgan Stanley also drew scrutiny previously for fielding an all-white, all-male slate of candidates to succeed former CEO ...